FLAG (chemotherapy)

FLAG (chemotherapy)

FLAG is a chemotherapy treatment protocol used primarily to treat acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The acronym stands for the drugs that are used in the treatment: Fludarabine, Cytarabine (also known as Ara-C), and Granulocyte colony-stimulating factor (G-CSF).

Treatment Protocol[edit | edit source]

The FLAG chemotherapy regimen is typically administered in a hospital setting due to the intensity of the treatment and the need for close monitoring of the patient. The treatment protocol involves the administration of Fludarabine and Cytarabine, followed by G-CSF. The G-CSF is used to stimulate the growth of new white blood cells, which are often depleted by the chemotherapy drugs.

Side Effects[edit | edit source]

Like all chemotherapy treatments, FLAG has potential side effects. These can include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include infection, bleeding, and anemia. Patients undergoing FLAG chemotherapy are closely monitored for these and other potential side effects.

Efficacy[edit | edit source]

The efficacy of the FLAG regimen varies depending on the specific type of leukemia or MDS being treated, as well as the individual patient's overall health and response to treatment. In general, FLAG is considered a high-intensity treatment protocol that can be effective in treating aggressive forms of leukemia and MDS.